Ardelyx (Nasdaq: ARDX) is a biopharmaceutical company dedicated to developing first-in-class medicines that improve the lives of people living with kidney disease and gastrointestinal conditions. The company's lead approved product, XPHOZAH (tenapanor), is an FDA-approved treatment for hyperphosphatemia in adults with chronic kidney disease on dialysis.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2016
Jun 2014
Aug 2011
Create a free account to see which investors have funded this company.
Create Free Account
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Clinical-stage biopharmaceutical company developing oral therapies for serious skeletal and cardi...
